In an adult with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia whose LDL‑cholesterol remains above target despite maximally tolerated statin therapy (or who is statin‑intolerant), how should PCSK9 inhibitors be initiated, dosed, and monitored?

PCSK9 Inhibitor Initiation, Dosing, and Monitoring

Add a PCSK9 inhibitor—either evolocumab 140 mg subcutaneously every 2 weeks (or 420 mg monthly) or alirocumab with comparable dosing—to the existing regimen of maximally tolerated statin plus ezetimibe 10 mg daily when LDL-C remains ≥70 mg/dL in very high-risk patients or ≥100 mg/dL in high-risk patients. 1

Patient Selection and Risk-Based Thresholds

Very high-risk patients (established ASCVD, recent ACS, diabetes with ASCVD, or heterozygous FH with ASCVD) warrant PCSK9 inhibitor therapy when:

• LDL-C remains ≥70 mg/dL (1.8 mmol/L) despite atorvastatin 80 mg or rosuvastatin 40 mg plus ezetimibe 10 mg 1
• The European Society of Cardiology issues a Class I, Level A recommendation for PCSK9 inhibitors when LDL-C remains ≥55 mg/dL (1.4 mmol/L) on maximal therapy 1

High-risk patients (established ASCVD without recent events, heterozygous FH without ASCVD) should receive PCSK9 inhibitors when:

• LDL-C remains ≥100 mg/dL (2.6 mmol/L) on maximally tolerated statin plus ezetimibe 1
• NICE guidelines approve therapy when LDL-C remains ≥135 mg/dL (3.5 mmol/L) despite statin plus ezetimibe 1

Specific Dosing Regimens

Evolocumab (Repatha)

• 140 mg subcutaneously every 2 weeks OR 420 mg subcutaneously once monthly 1
• Both dosing schedules produce equivalent LDL-C reductions of approximately 60% when added to statin therapy 2
• No dose adjustment required for renal or hepatic impairment 2

Alirocumab (Praluent)

• Comparable dosing and efficacy to evolocumab 1
• Provides similar 50–60% additional LDL-C reduction beyond statin plus ezetimibe 2

Critical point: Continue the maximally tolerated statin (atorvastatin 80 mg or rosuvastatin 40 mg) and ezetimibe 10 mg when adding the PCSK9 inhibitor—do not discontinue background therapy. 1, 2

Expected LDL-C Reductions

When PCSK9 inhibitors are added to maximally tolerated statin plus ezetimibe:

• Additional 40–65% LDL-C reduction beyond the baseline achieved with statin plus ezetimibe 1
• Real-world data demonstrate approximately 63% mean LDL-C reduction from pre-PCSK9i levels 3
• In heterozygous FH cohorts, 74% of patients achieve ≥50% LDL-C reduction after 12 months 4
• Total cholesterol decreases by approximately 39%, triglycerides by 19.5%, and HDL-C increases by 10.7% 3

Monitoring Protocol

Baseline Assessment (Before Initiation)

• Confirm LDL-C level on maximally tolerated statin plus ezetimibe for at least 4–12 weeks 2
• Document statin intensity: high-intensity defined as atorvastatin 40–80 mg or rosuvastatin 20–40 mg 2, 5
• Verify ezetimibe 10 mg daily is part of the regimen 1, 5
• Check hepatic transaminases and creatine kinase if not recently assessed 2

Follow-Up Lipid Monitoring

• Reassess LDL-C at 4–12 weeks after initiating PCSK9 inhibitor therapy 2
• Repeat lipid panel at 12 months to confirm sustained efficacy 4
• Monitor for LDL-C rebound after 24 months, as real-world data show slight increases from 1.7 mmol/L at 12 months to 1.9 mmol/L at ≥24 months 4

Safety Monitoring

• Injection site reactions are the most common adverse effect but rarely lead to discontinuation 6
• Myopathy risk remains <0.1% at guideline-recommended doses—far lower than with high-dose statins 2
• No routine laboratory monitoring (liver enzymes, CK) is required beyond standard statin monitoring 7, 6
• Serious adverse events occur at rates similar to placebo 6

Statin-Intolerant Patients

For patients who cannot tolerate any statin or only tolerate low-intensity statins:

• PCSK9 inhibitors remain highly effective when combined with ezetimibe alone 7, 4
• In real-world HeFH cohorts, 60% had statin intolerance yet still achieved mean 59% LDL-C reduction with PCSK9 inhibitor plus ezetimibe 4
• Statin intolerance is defined as documented intolerance to at least two different statins resulting in discontinuation 5

Important caveat: Statin intolerance alone does not justify PCSK9 inhibitor therapy—the LDL-C threshold criteria on maximally tolerated therapy (even if zero statin) must still be met. 5

Administration and Adherence

• Self-administered subcutaneous injection every 2 weeks or monthly 1
• Injection site rotation (abdomen, thigh, upper arm) minimizes local reactions 7
• Pre-filled pens or syringes simplify administration and improve adherence 7
• Real-world discontinuation rates are approximately 12%, primarily due to cost rather than adverse effects 4

Choice Between Evolocumab and Alirocumab

Both agents are equivalent in efficacy and safety—the choice is based on:

• Insurance formulary coverage and cost 6
• Patient preference for dosing frequency (every 2 weeks vs. monthly) 1
• Both have demonstrated cardiovascular outcomes benefits in the FOURIER (evolocumab) and ODYSSEY Outcomes (alirocumab) trials 8, 6

Do not use inclisiran as first-line PCSK9 inhibitor therapy—it lacks cardiovascular outcomes data until 2026–2027 and should be reserved only for patients with documented poor adherence to monoclonal antibodies or inability to self-inject. 8

Common Pitfalls to Avoid

• Do not add PCSK9 inhibitors before maximizing statin intensity and adding ezetimibe—high-intensity statin plus ezetimibe must be attempted first unless contraindicated 1, 2
• Do not discontinue statin or ezetimibe when starting PCSK9 inhibitor—triple therapy (statin + ezetimibe + PCSK9i) is the goal 1
• Do not combine PCSK9 monoclonal antibodies with inclisiran—there is no evidence or mechanistic rationale for dual PCSK9 inhibition 8
• Do not assume treatment failure if arbitrary LDL-C targets are not met—focus on maximally tolerated evidence-based therapy and relative risk reduction 2

Cost and Access Considerations

• PCSK9 inhibitors are expensive, but guideline bodies affirm that for very high-risk patients with persistent LDL-C elevation, the cardiovascular benefit justifies the cost 1
• Many insurance plans require prior authorization demonstrating failure of statin plus ezetimibe 5
• Treatment must often be prescribed through specialized lipid clinics or centers with expertise in advanced lipid management 5